INDEPENDENT ANALYSIS REVEALS THAT AUTHORIZED GENERICS ARE BAD FOR CONSUMERS, LEAD TO HIGHER PHARMACEUTICAL PRICES

The Generic Pharmaceutical Association (GPhA) unveiled an independent analysis of authorized generics that conclusively demonstrates that the anti-competitive brand pharmaceutical practice of introducing authorized generics (AGs) "significantly reduce incentives for independent generic firms to challenge invalid brand name patents and to develop non-infringing processes." This analysis also raised serious questions about the validity of a recent PhRMA study on authorized generics, noting that the PhRMA study contained significant errors making its conclusions questionable at best.
PR Newswire